Tag #Vaccine Regulation

Showing 1 to 4 of 4 results

abcnews.go.com

🌐 90% Global Worthiness

Aug 10, 01:15

Trump to Meet Putin in Alaska; Prasad Returns to FDA

President Trump announced a meeting with Vladimir Putin in Alaska on August 15, 2025, and Dr. Vinay Prasad is returning to his FDA position after a two-week absence following controversy.

Trump to Meet Putin in Alaska; Prasad Returns to FDA

President Trump announced a meeting with Vladimir Putin in Alaska on August 15, 2025, and Dr. Vinay Prasad is returning to his FDA position after a two-week absence following controversy.

Progress

48% Bias Score

ShareSaveArticle

Peace, Justice, and Strong Institutions

12345678

Previous 1 of 8 Next

What factors contributed to Prasad's initial departure and subsequent reinstatement?

The Trump-Putin meeting signifies a potential shift in US-Russia relations, while Prasad's reinstatement suggests the administration prioritizes specific FDA functions despite recent controversies. These events highlight competing priorities within the Trump administration.

cnn.com

🌐 85% Global Worthiness

May 1, 13:15

HHS Mandates Placebo Trials for All New Vaccines, Raising Covid-19 Booster Concerns

The US Department of Health and Human Services mandated placebo-controlled trials for all new vaccines before licensure, impacting Covid-19 booster distribution timelines and raising concerns among experts about increased risks to vulnerable populations, particularly the elderly (over 36,000 deaths ...

HHS Mandates Placebo Trials for All New Vaccines, Raising Covid-19 Booster Concerns

The US Department of Health and Human Services mandated placebo-controlled trials for all new vaccines before licensure, impacting Covid-19 booster distribution timelines and raising concerns among experts about increased risks to vulnerable populations, particularly the elderly (over 36,000 deaths ...

Progress

60% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate consequences of the HHS mandate requiring placebo-controlled trials for all new vaccines, and how will this impact the timely distribution of updated Covid-19 boosters?

The US Department of Health and Human Services (HHS) announced that all new vaccines will require placebo-controlled trials before licensure. This significantly alters previous practices and raises concerns about delays for updated Covid-19 vaccines, potentially jeopardizing vulnerable populations. The change comes as HHS criticizes existing vaccine safety monitoring systems as insufficient.

cnn.com

🌐 85% Global Worthiness

May 1, 07:15

HHS Mandates Placebo Trials for New Vaccines, Delaying COVID-19 Boosters

The US Department of Health and Human Services announced Wednesday that all new vaccines will require placebo-controlled trials before licensure, a change that experts warn could delay updated COVID-19 vaccines by months and put vulnerable populations at risk, despite assertions that current safety ...

HHS Mandates Placebo Trials for New Vaccines, Delaying COVID-19 Boosters

The US Department of Health and Human Services announced Wednesday that all new vaccines will require placebo-controlled trials before licensure, a change that experts warn could delay updated COVID-19 vaccines by months and put vulnerable populations at risk, despite assertions that current safety ...

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the HHS's justification for the new policy regarding vaccine safety monitoring systems compare with the assessments of independent experts?

This policy change represents a departure from the existing system for approving updated COVID-19 vaccines, which has mirrored the process for flu vaccines. Experts warn that requiring placebo-controlled trials will introduce significant delays in the vaccine update cycle, potentially leading to reduced protection against new viral strains, especially for vulnerable populations like the elderly. The HHS statement cites concerns about current vaccine safety monitoring systems, though experts dispute the claim that these systems are inadequate.

us.cnn.com

🌐 85% Global Worthiness

Mar 7, 01:10

Trump's FDA Nominee Plans to Review School Lunches, Abortion Pill, and Advisory Committees

President Trump's FDA nominee, Dr. Marty Makary, intends to review school lunches, the abortion pill mifepristone, and agency advisory committees, potentially leading to significant changes in FDA policies and practices.

Trump's FDA Nominee Plans to Review School Lunches, Abortion Pill, and Advisory Committees

President Trump's FDA nominee, Dr. Marty Makary, intends to review school lunches, the abortion pill mifepristone, and agency advisory committees, potentially leading to significant changes in FDA policies and practices.

Progress

40% Bias Score

ShareSaveArticle

Zero Hunger

12345678

Previous 1 of 8 Next

How do Makary's proposed actions relate to the broader policy goals of the Trump administration?

Makary's proposed changes reflect the Trump administration's broader focus on food policy and health concerns. His review of mifepristone will involve an expert coalition to analyze data and follow existing regulations, and he'll re-evaluate FDA advisory committee meetings, addressing concerns about potential conflicts of interest. These actions could significantly alter FDA policies and practices.

Showing 1 to 4 of 4 results